Eli Lilly and Co. said its MONARCH 2 trial of abemaciclib met the primary endpoint of progression-free survival. The phase III study evaluated abemaciclib, a cyclin-dependent kinase 4 and CDK 6 inhibitor, in combination with fulvestrant in women with hormone-receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer who have relapsed or progressed after endocrine therapy.
FDA has added stereotactic breast biopsy needles to its Medical Device Shortages List with an estimated duration of “through Q4 2026,” which spans July 1 to Sept. 30.
